The state of ready-made CAR-T

With CAR-T therapies costing hundreds of thousands of dollars and taking weeks of painstaking labor to custom-make for each patient, some companies and scientists are forging ahead on a different path: developing mass-produced, off-the-shelf CAR-T cells that could be used with any patient.

There's a long road ahead — only three early-stage clinical trials are underway — but scientists say these therapies, if successful, could have some significant advantages.

But first, researchers will have to overcome a fundamental feature of the human immune system, STAT's Ike Swetlitz reports.

Read more.